Skip to content
Review Open access

Antiplasmodial potential of Lansium domesticum Corrêa: A systematic review and critical appraisal of preclinical evidence

Aug 2026 · Magna Scientia Advanced Research and Reviews · 0 citations

Abstract

Background: Although Lansium domesticum Corrêa is widely used in Southeast Asian traditional medicine, its phytochemical diversity and antioxidant activity cannot be considered definitive evidence of antimalarial efficacy. A rigorous synthesis is required to distinguish specific anti-parasitic findings from data that only informs chemical characteristics or host-cell safety. Objective: This review aims to critically synthesize 17 species-specific primary studies published between 2016 and 2026 to differentiate direct antiplasmodial evidence from translational-enabling data. Methods: This systematic review was prospectively registered in PROSPERO (CRD420261458422). Systematic searches through July 2026 targeted studies reporting malaria-related endpoints. Evidence was classified as direct (whole-parasite assays, infected-animal models, or parasite-specific targets) or translational-enabling (phytochemical characterization, safety, or mechanistic evidence). Findings were synthesized narratively in accordance with the PRISMA 2020 statement and the Synthesis Without Meta-analysis (SWiM) reporting guideline. Results: Seventeen studies were identified: four provided direct evidence and 13 were enabling. Root chloroform and methanol fractions exhibited potent in vitro inhibition (IC50 1.4–3.6 µg/mL), yet in vivo stem-bark data showed a non-monotonic response and a high risk of bias. A significant unit discrepancy (mg/mL vs. µg/mL) was identified in reports for dukunolides, and in silico docking results lack experimental confirmation. Currently, no lead candidate possesses matched parasite-host selectivity, standardized chemistry, or pharmacokinetic data. Conclusion: Lansium domesticum is currently a source of preclinical leads rather than a validated antimalarial medicine. Future research must prioritize unit verification, standardized same-batch selectivity testing, mechanism validation, and rigorously controlled animal studies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.